TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05507710

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Near-infrared fluorescence imaging of perfusion
Description: Imaging with ICG near-infrared fluorescence is performed besides clinical judgement of the DIEP flap for perfusion evaluation. Based on fluorescence imaging, additional malperfused area(s) are resected.
Study: NCT05038059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethanolic extract of sapindus mukorossi
Description: ethanolic extract will be used as final endodontic irrigant during root canal procedures in extracted teeth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethylene diamine tetra acetic acid
Description: used as final endodontic irrigant in root canal therapy
Study: NCT02106338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
Study: NCT04198623

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast 10 Mg Oral Tablet
Description: Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment
Study: NCT04870567

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High dose rate brachytherapy
Description: Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
Study: NCT01429545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban and nifedipine
Description: This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (\<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
Study: NCT01889589

Intervention type: OTHER
Intervention: Surveillance
Study: NCT02908438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotrophin releasing hormone agonist(GnRHa)
Description: GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
Study: NCT02984501

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by CTV with a safety margin of 1cm in all directions to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a 15-MV linear accelerator (Varian Medical System) with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied for all patients with periodical digital portal images to evaluate the precision of the set-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
Study: NCT00745732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (ZACTIMA)
Description: ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day.
Study: NCT00398632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
Study: NCT01093040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-354
Description: 150 mg CAT-354 or placebo given SC on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-354
Description: 300 mg CAT-354 or placebo given SC on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 354
Description: 600 mg CAT-354 or placebo given SC on Day 1
Study: NCT01754480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant Grifols
Description: Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel®
Description: Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
Study: NCT01341158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human interferon-α
Description: Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks
Study: NCT01845090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum carbonate
Description: the effect on serum FGF23

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate 500mg\~1000 mg tid for 6 months
Study: NCT02827188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mega Team-videogame
Description: Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 30-35 minutes a day, approximately 5 days a week for a minimum of 21 days and a maximum of 25 days.
Study: NCT01071395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Amantadine hydrochloride 300mg daily in three divided doses
Study: NCT00927537

Intervention type: DRUG
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide
Description: Patients under daily life treatment receiving Kinzalplus according to local drug information.
Study: NCT01071395

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill given 3 times daily
Study: NCT02805257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Description: Intraoperative and postoperative injections of mitomycin-c/Mitosol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Balanced Salt Solution
Description: Intraoperative and postoperative injections of BSS

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ahmed Glaucoma Valve Implant
Description: Implantation of Ahmed Valve in study eye

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Valve Implant
Description: Implantation of Ahmed Valve in study eye
Study: NCT00185848

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]FHBG
Description: \< 7mCi and 2 ug, iv
Study: NCT04350073

Intervention type: DEVICE
Intervention: Q-NRG Metobolic Cart Device
Description: COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.

Intervention type: DEVICE
Intervention: Q-NRG Metobolic Cart Device
Description: COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.

Intervention type: DEVICE
Intervention: MuscleSound Ultrasound
Description: COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.

Intervention type: DEVICE
Intervention: MuscleSound Ultrasound
Description: COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.

Intervention type: DEVICE
Intervention: Multifrequency Bioimpedance Spectroscopy
Description: COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
Study: NCT03362684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: FOLFOX-4 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX-4 every 2 weeks
Study: NCT04350073

Intervention type: DEVICE
Intervention: Multifrequency Bioimpedance Spectroscopy
Description: COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
Study: NCT00905333

Intervention type: DRUG
Group type: OTHER
Intervention: Candesartan (test)
Description: 16 mg oral tablet, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Felodipine (test)
Description: 5 mg oral extended release tablet, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Candesartan Cilexetil
Description: 16 mg oral tablet, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Felodipine
Description: 5 mg oral extended release tablet, single dose
Study: NCT01274273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: 2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa-2b
Description: IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
Study: NCT04250896

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Standard child care in health unit plus exposure to EsIAN

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS´s sending by cell phone for behavior change
Description: SMS messages sent through a cell pone through the RapidPro platform on practices related to the prevention of infant malnutrition to primary caregivers and the strengthening of counseling for the prevention of infant malnutrition with health providers.
Study: NCT03443973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
Study: NCT01059552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: vorinostat once daily for 12 weeks of therapy
Study: NCT04361552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV
Study: NCT02766608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Description: Blinded Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 160/9.6 μg
Description: Blinded Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI 9.6 μg
Description: Blinded Treatment
Study: NCT03347474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral surgical implantation of DBS system to NAc
Description: The Medtronic, PINS and SceneRay DBS device will be utilized in the present study.
Study: NCT03881722

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mg alginate
Description: Mg alginate after feedings

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mg alginate
Description: Mg alginate after feedings
Study: NCT01019278

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam radiation therapy
Description: Undergo external proton beam radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy treatment planning/simulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT02766608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 320 μg
Description: Blinded Treatment
Study: NCT03360071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allergen Immunotherapy Extract
Description: Allergen Immunotherapy treatment mixture to be delivered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allergen Immunotherapy Control
Description: Allergen Immunotherapy Control Solution to be delivered subcutaneously
Study: NCT01671371

Intervention type: OTHER
Group type: OTHER
Intervention: Point-of-Care Ultrasound
Description: Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
Study: NCT02766608

Intervention type: DRUG
Group type: OTHER
Intervention: Symbicort® TBH 400/12 μg BID
Description: Open Label
Study: NCT01363323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Description: Dose 3
Study: NCT03368872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Astaxanthin formulation
Description: Astaxanthin formulation containing AstaReal® astaxanthin (Haematococcus pluvialis algae extract), tocotrienol, and zinc will be orally administered starting on Day 1 until Day 120

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be orally administered starting on Day 1 until Day 120.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The subjects will undergo interval treadmill incline protocol (target 85% HR max, 3 times a week for 40 to 60 minutes) starting on Day 31 until Day 120.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training
Description: The subjects will undergo interval treadmill incline protocol (target 85% HR max, 3 times a week for 40 to 60 minutes) starting on Day 31 until Day 120.
Study: NCT03208218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYP-1512
Description: Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revlimid cap
Description: Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)
Study: NCT02368119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOADC069-00-vp
Description: IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOADC069-00-vp
Description: IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOADC069-00-vp
Description: IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOADC069-00-vp
Description: IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-EbolaZ
Description: IM injection of MVA-EbolaZ vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-EbolaZ
Description: IM injection of MVA-EbolaZ vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM injection injection of Phosphate Buffered Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM injection injection of Phosphate Buffered Saline
Study: NCT04464382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient (OA)
Description: Patients who are candidates for OA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the OA group (case group), he will be discharged on an outpatient basis from the post-surgical stay unit without requiring hospital admission.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hospitalization appendectomy (HA)
Description: Patients who are candidates for HA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the case group (HA), he will be admitted in hospital beds.
Study: NCT01456494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teach-to-Goal Education
Description: Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
Study: NCT01406769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bioelectric Impedance Analysis
Description: Undergo preoperative and postoperative lower-extremity lymphedema assessment
Study: NCT01363323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study: NCT01977911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cell based tissue engineered partial laryngeal implants
Description: Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.
Study: NCT04612270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: Two venous blood collections in within one week. No drug-related intervention in-vivo.